Acro Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2019
March 27, 2020 at 03:00 pm
Share
Acro Biomedical Co., Ltd. announced earnings results for the first quarter ended December 31, 2019. For the first quarter, the company announced sales was USD 193,536 compared to USD 1.354 million a year ago. Operating loss was USD 75,433 compared to USD 94,235 a year ago. Net loss was USD 75,873 compared to USD 75,016 a year ago.
Acro Biomedical Co., Ltd. is principally engaged in the business is the sale of cordyceps related products. The Company is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The Company's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus, which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The Company is involved in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. It sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.
ACRO BIOMEDICAL CO., LTD. 
